CN100460005C - Medicine composition for treating rheumatism and rheumatoid arthritis - Google Patents
Medicine composition for treating rheumatism and rheumatoid arthritis Download PDFInfo
- Publication number
- CN100460005C CN100460005C CNB2006100078800A CN200610007880A CN100460005C CN 100460005 C CN100460005 C CN 100460005C CN B2006100078800 A CNB2006100078800 A CN B2006100078800A CN 200610007880 A CN200610007880 A CN 200610007880A CN 100460005 C CN100460005 C CN 100460005C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- pharmaceutical composition
- dosage form
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a Chinese medicine for effectively curing rheumatic and rheumatoid arthritides with obvious therapeutic effect. Said Chinese medicine is made up by using 12 Chinese medicinal materials of nux vomica, aconite main tuber, wild aconite tuber, cinnamon twig, white peony root, myrrh and others through a certain preparation process.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of rheumatism atrophic arthritis.
Background technology
Rheumatism is that a kind of common, frequently-occurring disease, the course of disease are longer, the stubborn disease that the clinical symptoms performance is various, the treatment phase is long, because of this sick cause of disease, the pathogenesis more complicated, clinically be marginality, multidisciplinary performance more, all control and the research work of such pathological changes is brought certain difficulty to clinical dialectical executing.In motherland's medical science, rheumatism is collectively referred to as arthromyodynia.A Plain Questions of Huangdi's Internal Classic numbness opinion piece of writing the 43 " say: wet three gas of wind and cold assorted to close be numbness also " " its domination of wind then is migratory arthralgia, and domination of cold then is an arthralgia aggravated by cold, and domination of damp pathogen then is a damp arthralgia." this disease Therapeutic Principle be when being to dispel the wind, win wet, dispelling cold by warming the meridian, wind-cold damp pathogen gas dispeled and disease is separated.According to former worthies' symposium on medical topics, the rule of treatment, square medicine reaches at present to rheumatismal clinical research, by the clinical observation on the therapeutic effect to 1028 routine rheumatism patients, has obtained clinical effectiveness preferably.Have onset rapidly, determined curative effect, compare with similar medicine, its short term effect and late result are all more satisfactory.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition that the treatment rheumatism atrophic arthritis is had remarkable result.
The present invention is achieved through the following technical solutions:
Semen Strychni 10-30 weight portion Radix Aconiti 15-45 weight portion Radix Aconiti Kusnezoffii 15-45 weight portion
Ramulus Cinnamomi 15-45 weight portion Radix Paeoniae Alba 10-30 weight portion Herba Ephedrae 20-60 weight portion
Radix Saposhnikoviae 15-45 weight portion Rhizoma Atractylodis Macrocephalae 10-30 weight portion Olibanum 15-45 weight portion
Myrrha 15-45 weight portion Semen Coicis 10-30 weight portion Radix Ginseng 15-45 weight portion
The optimum ratio of pharmaceutical composition of the present invention is:
Semen Strychni 20 weight portion Radix Aconitis 30 weight portion Radix Aconiti Kusnezoffii 30 weight portions
The Ramulus Cinnamomi 30 weight portion Radix Paeoniae Albas 20 weight portion Herba Ephedraes 40 weight portions
The Radix Saposhnikoviae 30 weight portion Rhizoma Atractylodis Macrocephalaes 20 weight portion Olibanums 30 weight portions
Myrrha 30 weight portion Semen Coiciss 20 weight portion Radix Ginsengs 30 weight portions
Described Semen Strychni is a Semen Strychni (processed), and Radix Aconiti is a Radix Aconiti Preparata, and Radix Aconiti Kusnezoffii is a Radix Aconiti Kusnezoffii Preparata, and Olibanum is an Olibanum (processed), and Myrrha is a Myrrha (processed).
Pharmaceutical composition of the present invention adds acceptable accessories and makes clinical any dosage form of accepting.As tablet (coated tablet, Film coated tablets, enteric coated tablet, buccal tablet, dispersible tablet, oral cavity disintegration tablet), capsule, soft capsule, oral liquid, syrup, granule, pill, powder, spray, unguentum, injection, injection lyophilized powder, injection infusion solutions, suppository, drop pill, slow releasing preparation or controlled release preparation etc.
Pharmaceutical composition tool expelling wind and cold of the present invention, promoting the flow of QI in the collateral by warming the meridian, spleen invigorating eliminating dampness by diuresis, consolidate the effect of setting upright, remarkable to treatment rheumatism atrophic arthritis effect.
Following experimental example is used to further specify the present invention:
Clinical efficacy
1, physical data
In sick 1028 examples of pharmaceutical composition clinical observation of the present invention, male 570 people, women 458 people are the oldest 72 years old, minimum 15 years old, surplus the course of disease the longest 20 year, the shortest 1 month.Be rheumatism all through clinical definite.
2, Therapeutic Method
Medicine is formed: Semen Strychni (processed) 20g, Radix Aconiti Preparata 30g, Radix Aconiti Kusnezoffii Preparata 30g, Ramulus Cinnamomi 30g, Radix Paeoniae Alba 20g, Herba Ephedrae 40g, Radix Saposhnikoviae 30g, Rhizoma Atractylodis Macrocephalae 20g, Olibanum (processed) 30g, Myrrha (processed) 30g, Semen Coicis 20g, Radix Ginseng 30g.
Said medicine technology pulverizing is routinely made capsule, every 0.4g.
Usage: each 4, every day three times, one after each meal.
3, criterion of therapeutical effect
Cure: transference cure, joint motion is normal, lab testing is normal;
Take a turn for the better: symptom is clearly better, lab testing has improvement;
Do not heal: symptom and experiment examination are checked not have and are improved.
4, therapeutic outcome
In the clinical observation 1028 routine cases of the present invention, wherein cure 729 examples, 178 examples that take a turn for the better, 121 examples that do not heal, total effective rate 88.23%.
5, model case
Case 1: Lee, woman, 39 years old, civilian worker, first visit on March 18 in 2003.The main suit: the big joint congestion and swelling pain of extremity 1 month, patient's cold of living is overworked, and occurs the big joint congestion and swelling pain of extremity before 1 month, and is movable unfavorable.Oral aspirin and meticorten, the intramuscular injection penicillin takes a turn for the better, but stomach discomfort after 5 days, inappetence, the tired power of body, pale tongue with white fur, stringy pulse.The heavy 60mm/h that has a blood test, anti-chain 0 is normal, leukocyte 9 * 10
9/ L, hemoglobin 95g/L.Diagnosis: rheumatoid arthritis.Take the eliminating evil collateral dredging capsule of the present invention, each 4, every day 3 times, above-mentioned symptom disappears after 30 days.
Case 2: Song, man, 26 years old, vegetable retail employee.In December, 2003 is gone to a doctor, and suffers from rheumatoid arthritis 9 months, begins once to live this county hospital one month, clinical recovery when ill.Leave hospital back January, the double knee joint swelling pain occurs, the whole body fear of cold, activity still can, the pale tongue white and thin fur, tense pulse, erythrocyte sedimentation rate 30mm/h, anti-0 is normal.Differential diagnosis in tcm: the wind and cold invasion, numbness resistance meridians, card belongs to arthralgia aggravated by cold.Take the eliminating evil collateral dredging capsule of the present invention, each 4, every day 3 times, check after 2 months, end recurrence.
Following embodiment is used to further specify the present invention:
Embodiment 1:
Semen Strychni (processed) 20kg Radix Aconiti Preparata 30kg Radix Aconiti Kusnezoffii Preparata 30kg Ramulus Cinnamomi 30kg
Radix Paeoniae Alba 20kg Herba Ephedrae 40kg Radix Saposhnikoviae 30kg Rhizoma Atractylodis Macrocephalae 20kg
Olibanum (processed) 30kg Myrrha (processed) 30kg Semen Coicis 20kg Radix Ginseng 30kg
Said medicine technology is routinely made capsule, every 0.4g, each 4, every day three times, one after each meal.
Embodiment 2:
Semen Strychni (processed) 15kg Radix Aconiti Preparata 40kg Radix Aconiti Kusnezoffii Preparata 20kg Ramulus Cinnamomi 20kg
Radix Paeoniae Alba 25kg Herba Ephedrae 30kg Radix Saposhnikoviae 35kg Rhizoma Atractylodis Macrocephalae 15kg
Olibanum (processed) 40kg Myrrha (processed) 20kg Semen Coicis 25kg Radix Ginseng 40kg
Said medicine technology is routinely made oral liquid.
Embodiment 3:
Semen Strychni 25kg Radix Aconiti 20kg Radix Aconiti Kusnezoffii 40kg Ramulus Cinnamomi 40kg
Radix Paeoniae Alba 15kg Herba Ephedrae 50kg Radix Saposhnikoviae 25kg Rhizoma Atractylodis Macrocephalae 25kg
Olibanum 20kg Myrrha 40kg Semen Coicis 15kg Radix Ginseng 40kg
Said medicine technology is routinely made injection.
Embodiment 4:
Semen Strychni 20kg Radix Aconiti 30kg Radix Aconiti Kusnezoffii 30kg Ramulus Cinnamomi 30kg
Radix Paeoniae Alba 20kg Herba Ephedrae 40kg Radix Saposhnikoviae 30kg Rhizoma Atractylodis Macrocephalae 20kg
Olibanum 30kg Myrrha 30kg Semen Coicis 20kg Radix Ginseng 30kg
Said medicine add conventional adjuvant routinely technology make lyophilized injectable powder.
Embodiment 5:
Semen Strychni (processed) 15kg Radix Aconiti Preparata 40kg Radix Aconiti Kusnezoffii Preparata 20kg Ramulus Cinnamomi 20kg
Radix Paeoniae Alba 25kg Herba Ephedrae 30kg Radix Saposhnikoviae 35kg Rhizoma Atractylodis Macrocephalae 15kg
Olibanum (processed) 40kg Myrrha (processed) 20kg Semen Coicis 25kg Radix Ginseng 40kg
Said medicine add conventional adjuvant routinely technology make slow releasing preparation.
Embodiment 6:
Semen Strychni (processed) 25kg Radix Aconiti Preparata 20kg Radix Aconiti Kusnezoffii Preparata 40kg Ramulus Cinnamomi 40kg
Radix Paeoniae Alba 15kg Herba Ephedrae 50kg Radix Saposhnikoviae 25kg Rhizoma Atractylodis Macrocephalae 25kg
Olibanum (processed) 20kg Myrrha (processed) 40kg Semen Coicis 15kg Radix Ginseng 40kg
Said medicine add conventional adjuvant routinely technology make drop pill.
Embodiment 7:
Semen Strychni 20kg Radix Aconiti 30kg Radix Aconiti Kusnezoffii 30kg Ramulus Cinnamomi 30kg
Radix Paeoniae Alba 20kg Herba Ephedrae 40kg Radix Saposhnikoviae 30kg Rhizoma Atractylodis Macrocephalae 20kg
Olibanum 30kg Myrrha 30kg Semen Coicis 20kg Radix Ginseng 30kg
Said medicine add conventional adjuvant routinely technology make spray.
Embodiment 8:
Semen Strychni 20kg Radix Aconiti 30kg Radix Aconiti Kusnezoffii 30kg Ramulus Cinnamomi 30kg
Radix Paeoniae Alba 20kg Herba Ephedrae 40kg Radix Saposhnikoviae 30kg Rhizoma Atractylodis Macrocephalae 20kg
Olibanum 30kg Myrrha 30kg Semen Coicis 20kg Radix Ginseng 30kg
Said medicine technology is routinely made unguentum.
Embodiment 9:
Semen Strychni 20kg Radix Aconiti 30kg Radix Aconiti Kusnezoffii 30kg Ramulus Cinnamomi 30kg
Radix Paeoniae Alba 20kg Herba Ephedrae 40kg Radix Saposhnikoviae 30kg Rhizoma Atractylodis Macrocephalae 20kg
Olibanum 30kg Myrrha 30kg Semen Coicis 20kg Radix Ginseng 30kg
Said medicine technology is routinely made suppository.
Claims (14)
1. pharmaceutical composition for the treatment of rheumatism atrophic arthritis is characterized in that said composition made by following crude drug:
Semen Strychni 10-30 weight portion Radix Aconiti 15-45 weight portion Radix Aconiti Kusnezoffii 15-45 weight portion
Ramulus Cinnamomi 15-45 weight portion Radix Paeoniae Alba 10-30 weight portion Herba Ephedrae 20-60 weight portion
Radix Saposhnikoviae 15-45 weight portion Rhizoma Atractylodis Macrocephalae 10-30 weight portion Olibanum 15-45 weight portion
Myrrha 15-45 weight portion Semen Coicis 10-30 weight portion Radix Ginseng 15-45 weight portion.
2. pharmaceutical composition according to claim 1 is characterized in that said composition made by following crude drug:
Semen Strychni 20 weight portion Radix Aconitis 30 weight portion Radix Aconiti Kusnezoffii 30 weight portions
The Ramulus Cinnamomi 30 weight portion Radix Paeoniae Albas 20 weight portion Herba Ephedraes 40 weight portions
The Radix Saposhnikoviae 30 weight portion Rhizoma Atractylodis Macrocephalaes 20 weight portion Olibanums 30 weight portions
Myrrha 30 weight portion Semen Coiciss 20 weight portion Radix Ginsengs 30 weight portions.
3. pharmaceutical composition according to claim 1 is characterized in that said composition made by following crude drug:
Semen Strychni 15 weight portion Radix Aconitis 40 weight portion Radix Aconiti Kusnezoffii 20 weight portions
The Ramulus Cinnamomi 20 weight portion Radix Paeoniae Albas 25 weight portion Herba Ephedraes 30 weight portions
The Radix Saposhnikoviae 35 weight portion Rhizoma Atractylodis Macrocephalaes 15 weight portion Olibanums 40 weight portions
Myrrha 20 weight portion Semen Coiciss 25 weight portion Radix Ginsengs 40 weight portions.
4. pharmaceutical composition according to claim 1 is characterized in that said composition made by following crude drug:
Semen Strychni 25 weight portion Radix Aconitis 20 weight portion Radix Aconiti Kusnezoffii 40 weight portions
The Ramulus Cinnamomi 40 weight portion Radix Paeoniae Albas 15 weight portion Herba Ephedraes 50 weight portions
The Radix Saposhnikoviae 25 weight portion Rhizoma Atractylodis Macrocephalaes 25 weight portion Olibanums 20 weight portions
Myrrha 40 weight portion Semen Coiciss 15 weight portion Radix Ginsengs 40 weight portions.
5. according to the described pharmaceutical composition of one of claim 1-4, it is characterized in that described Semen Strychni is a Semen Strychni (processed), Radix Aconiti is a Radix Aconiti Preparata, and Radix Aconiti Kusnezoffii is a Radix Aconiti Kusnezoffii Preparata, and Olibanum is an Olibanum (processed), and Myrrha is a Myrrha (processed).
6. according to the described pharmaceutical composition of one of claim 1-4, it is characterized in that adding the adjuvant of pharmaceutically accepting and make any dosage form of clinical acceptance.
7. the dosage form of pharmaceutical composition according to claim 6 is characterized in that described dosage form is tablet, capsule, oral liquid, granule, pill, powder, spray, unguentum, injection or suppository.
8. the dosage form of pharmaceutical composition according to claim 6 is characterized in that described dosage form is soft capsule, syrup, drop pill or injection lyophilized powder.
9. the dosage form of pharmaceutical composition according to claim 6 is characterized in that described dosage form is the injection infusion solutions.
10. the dosage form of pharmaceutical composition according to claim 6 is characterized in that described dosage form is a slow releasing preparation.
11. the dosage form of pharmaceutical composition according to claim 6 is characterized in that described dosage form is a controlled release preparation.
12. the dosage form of pharmaceutical composition according to claim 7 is characterized in that described tablet is coated tablet, Film coated tablets or enteric coated tablet.
13. the dosage form of pharmaceutical composition according to claim 7 is characterized in that described tablet is buccal tablet or dispersible tablet.
14. according to the application of the described pharmaceutical composition of one of claim 1-4 in the medicine of preparation treatment rheumatism atrophic arthritis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100078800A CN100460005C (en) | 2006-02-23 | 2006-02-23 | Medicine composition for treating rheumatism and rheumatoid arthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100078800A CN100460005C (en) | 2006-02-23 | 2006-02-23 | Medicine composition for treating rheumatism and rheumatoid arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101024050A CN101024050A (en) | 2007-08-29 |
CN100460005C true CN100460005C (en) | 2009-02-11 |
Family
ID=38742892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100078800A Expired - Fee Related CN100460005C (en) | 2006-02-23 | 2006-02-23 | Medicine composition for treating rheumatism and rheumatoid arthritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100460005C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496849B (en) * | 2008-01-31 | 2012-06-27 | 邹方昕 | Chinese medicine preparation for treating atrophic arthritis |
CN101417095B (en) * | 2008-12-01 | 2011-10-05 | 狄丽哲 | Medicine for treating arthrodynia |
CN109528950A (en) * | 2018-12-13 | 2019-03-29 | 洪湖市中医医院 | A kind of cold extermination TONGBI PIAN and preparation method thereof |
CN113274475B (en) * | 2021-05-31 | 2022-02-22 | 苏州大学 | Traditional Chinese medicine for treating rheumatoid arthritis |
-
2006
- 2006-02-23 CN CNB2006100078800A patent/CN100460005C/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
三十四例风湿性关节炎疗效观察. 李振华.湖北中医杂志,第2期. 1984 |
三十四例风湿性关节炎疗效观察. 李振华.湖北中医杂志,第2期. 1984 * |
桂枝芍药知母汤加减治疗痹症. 胡建华.上海中医药杂志,第3期. 1983 |
桂枝芍药知母汤加减治疗痹症. 胡建华.上海中医药杂志,第3期. 1983 * |
Also Published As
Publication number | Publication date |
---|---|
CN101024050A (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912593B (en) | Medicament for treating dysmenorrheal and preparation method thereof | |
CN102008655B (en) | Traditional Chinese medicine composition for treating arthralgia and preparation method thereof | |
CN100460005C (en) | Medicine composition for treating rheumatism and rheumatoid arthritis | |
CN101670011A (en) | Medicament for treating rheumatism and rheumatoid and preparation method thereof | |
CN102698014A (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
CN103599474B (en) | A kind of Chinese medicine composition being used for the treatment of poor sleeping quality | |
CN105381132A (en) | Drug for treating thyroid nodule | |
CN104435519A (en) | Pharmaceutical composition for treating primary dysmenorrhea | |
CN103705846B (en) | The Chinese medicine preparation for the treatment of ovarian cyst | |
CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
CN103083433A (en) | Drug for treating rheumatism and rheumatoid sciatica | |
CN105194584A (en) | Medicine for treating dysmenorrhea | |
CN104399055A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis | |
CN101658636B (en) | Chinese medical composition for treating coronary heart disease | |
CN104208532A (en) | Drug for treating erythrodermic psoriasis | |
CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
CN102205096A (en) | Medicament for treating adnexitis and pelvic inflammation | |
CN101647880A (en) | Medicament for treating appendicitis and preparation method thereof | |
CN101912570B (en) | Medicinal composition for treating rheumatism and preparation method thereof | |
CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
CN1839974B (en) | Medicine composition for treating rheumatoid disease and method for preparing the same | |
CN101129718B (en) | Traditional Chinese medicine preparation for treating leuoderma | |
CN1695697A (en) | Medication for treating ache of rheumatoid arthritis | |
CN101361934B (en) | Traditional Chinese medicine preparation for treating arthritis and various osteonosus | |
CN102670740A (en) | Drug composition for treating soft tissue injuries and preparation process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090211 Termination date: 20110223 |